Valuation: Celltrion, Inc.

Market Cap 40,729B 27.89B 24.5B 22.78B 20.9B 39.28B 2,686B 39.88B 271B 106B 1,320B 105B 102B 4,565B P/E 2026 *
27.4x
P/E 2027 * 24.3x
Enterprise Value 42.77B 29.29M 25.72M 23.92M 21.95M 41.25M 2.82B 41.88M 284M 111M 1.39B 110M 108M 4.79B EV / Sales 2026 *
8.04x
EV / Sales 2027 * 6.82x
Free-Float
58.02%
Yield 2026 *
0.41%
Yield 2027 * 0.45%
Manager TitleAgeSince
Chief Executive Officer 65 2015-03-19
Chief Executive Officer 42 2021-03-25
President 50 2026-02-12
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 2005-03-31
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
-0.24%-0.72%+21.81%-16.94% 11.16B
Average -0.15%+0.43%+56.69%+99.21% 25.39B
Weighted average by Cap. +0.12%+0.59%+80.82%+140.76%

Financials

2026 *2027 *
Net sales 5,321B 3.64B 3.2B 2.98B 2.73B 5.13B 351B 5.21B 35.34B 13.81B 173B 13.68B 13.38B 596B 6,181B 4.23B 3.72B 3.46B 3.17B 5.96B 408B 6.05B 41.05B 16.04B 200B 15.89B 15.55B 693B
Net income 1,484B 1.02B 892M 830M 761M 1.43B 97.83B 1.45B 9.85B 3.85B 48.1B 3.81B 3.73B 166B 1,698B 1.16B 1.02B 950M 872M 1.64B 112B 1.66B 11.28B 4.41B 55.05B 4.37B 4.27B 190B
Net Debt 2,041B 1.4B 1.23B 1.14B 1.05B 1.97B 135B 2B 13.56B 5.3B 66.18B 5.25B 5.13B 229B 1,427B 977M 859M 798M 733M 1.38B 94.13B 1.4B 9.48B 3.7B 46.28B 3.67B 3.59B 160B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A